206 related articles for article (PubMed ID: 36588692)
21. Targeting Bruton's Tyrosine Kinase in Inflammatory and Autoimmune Pathologies.
Neys SFH; Hendriks RW; Corneth OBJ
Front Cell Dev Biol; 2021; 9():668131. PubMed ID: 34150760
[TBL] [Abstract][Full Text] [Related]
22. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
Yahiaoui A; Meadows SA; Sorensen RA; Cui ZH; Keegan KS; Brockett R; Chen G; Quéva C; Li L; Tannheimer SL
PLoS One; 2017; 12(2):e0171221. PubMed ID: 28178345
[TBL] [Abstract][Full Text] [Related]
23. Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies.
Wang Y; Zhang LL; Champlin RE; Wang ML
Clin Pharmacol Ther; 2015 May; 97(5):455-68. PubMed ID: 25669675
[TBL] [Abstract][Full Text] [Related]
24. Activation loop dynamics determine the different catalytic efficiencies of B cell- and T cell-specific tec kinases.
Joseph RE; Kleino I; Wales TE; Xie Q; Fulton DB; Engen JR; Berg LJ; Andreotti AH
Sci Signal; 2013 Aug; 6(290):ra76. PubMed ID: 23982207
[TBL] [Abstract][Full Text] [Related]
25. HZ-A-005, a potent, selective, and covalent Bruton's tyrosine kinase inhibitor in preclinical development.
Huang W; Wang S; Zhang Z; Zhang C; Zeng S; Liang M; Shen Z; Liu X
Bioorg Chem; 2020 Dec; 105():104377. PubMed ID: 33091668
[TBL] [Abstract][Full Text] [Related]
26. Role(s) of IL-2 inducible T cell kinase and Bruton's tyrosine kinase in mast cell response to lipopolysaccharide.
Huang W; August A
Genom Data; 2016 Jun; 8():18-20. PubMed ID: 27081634
[TBL] [Abstract][Full Text] [Related]
27. Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment.
Stiff A; Trikha P; Wesolowski R; Kendra K; Hsu V; Uppati S; McMichael E; Duggan M; Campbell A; Keller K; Landi I; Zhong Y; Dubovsky J; Howard JH; Yu L; Harrington B; Old M; Reiff S; Mace T; Tridandapani S; Muthusamy N; Caligiuri MA; Byrd JC; Carson WE
Cancer Res; 2016 Apr; 76(8):2125-36. PubMed ID: 26880800
[TBL] [Abstract][Full Text] [Related]
28. Bruton's Tyrosine Kinase and Its Isoforms in Cancer.
Wang X; Kokabee L; Kokabee M; Conklin DS
Front Cell Dev Biol; 2021; 9():668996. PubMed ID: 34307353
[TBL] [Abstract][Full Text] [Related]
29. Bruton's tyrosine kinase (BTK) as a promising target in solid tumors.
Molina-Cerrillo J; Alonso-Gordoa T; Gajate P; Grande E
Cancer Treat Rev; 2017 Jul; 58():41-50. PubMed ID: 28641100
[TBL] [Abstract][Full Text] [Related]
30. Structural Complementarity of Bruton's Tyrosine Kinase and Its Inhibitors for Implication in B-Cell Malignancies and Autoimmune Diseases.
Najmi A; Thangavel N; Mohanan AT; Qadri M; Albratty M; Ashraf SE; Saleh SF; Nayeem M; Mohan S
Pharmaceuticals (Basel); 2023 Mar; 16(3):. PubMed ID: 36986499
[TBL] [Abstract][Full Text] [Related]
31. A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk
Gui F; Jiang J; He Z; Li L; Li Y; Deng Z; Lu Y; Wu X; Chen G; Su J; Song S; Zhang YM; Yun CH; Huang X; Weisberg E; Zhang J; Deng X
Br J Pharmacol; 2019 Dec; 176(23):4491-4509. PubMed ID: 31364164
[TBL] [Abstract][Full Text] [Related]
32. A review of Bruton's tyrosine kinase inhibitors in multiple sclerosis.
Airas L; Bermel RA; Chitnis T; Hartung HP; Nakahara J; Stuve O; Williams MJ; Kieseier BC; Wiendl H
Ther Adv Neurol Disord; 2024; 17():17562864241233041. PubMed ID: 38638671
[TBL] [Abstract][Full Text] [Related]
33. Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia.
Wu H; Hu C; Wang A; Weisberg EL; Chen Y; Yun CH; Wang W; Liu Y; Liu X; Tian B; Wang J; Zhao Z; Liang Y; Li B; Wang L; Wang B; Chen C; Buhrlage SJ; Qi Z; Zou F; Nonami A; Li Y; Fernandes SM; Adamia S; Stone RM; Galinsky IA; Wang X; Yang G; Griffin JD; Brown JR; Eck MJ; Liu J; Gray NS; Liu Q
Leukemia; 2016 Jan; 30(1):173-81. PubMed ID: 26165234
[TBL] [Abstract][Full Text] [Related]
34. ABBV-105, a selective and irreversible inhibitor of Bruton's tyrosine kinase, is efficacious in multiple preclinical models of inflammation.
Goess C; Harris CM; Murdock S; McCarthy RW; Sampson E; Twomey R; Mathieu S; Mario R; Perham M; Goedken ER; Long AJ
Mod Rheumatol; 2019 May; 29(3):510-522. PubMed ID: 29862859
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of Bruton's Tyrosine Kinase Suppresses Cancer Stemness and Promotes Carboplatin-induced Cytotoxicity Against Bladder Cancer Cells.
Pan Y; Chiu YH; Chiu SC; Cho DY; Lee LM; Wen YC; Whang-Peng J; Hsiao CH; Shih PH
Anticancer Res; 2020 Nov; 40(11):6093-6099. PubMed ID: 33109547
[TBL] [Abstract][Full Text] [Related]
36. Investigation of the anti-tumor mechanism of tirabrutinib, a highly selective Bruton's tyrosine kinase inhibitor, by phosphoproteomics and transcriptomics.
Kozaki R; Yasuhiro T; Kato H; Murai J; Hotta S; Ariza Y; Sakai S; Fujikawa R; Yoshida T
PLoS One; 2023; 18(3):e0282166. PubMed ID: 36897912
[TBL] [Abstract][Full Text] [Related]
37. Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma.
Tanaka H; Kaneko N; Sakagami H; Matsuya T; Hiramoto M; Yamanaka Y; Mori M; Koshio H; Hirano M; Takeuchi M
Leuk Res; 2020 Jan; 88():106286. PubMed ID: 31865062
[TBL] [Abstract][Full Text] [Related]
38. Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase.
Davids MS; Brown JR
Future Oncol; 2014 May; 10(6):957-67. PubMed ID: 24941982
[TBL] [Abstract][Full Text] [Related]
39. [
Skaddan MB; Wooten DW; Wilcox KC; Voorbach MJ; Reuter DR; Jia ZJ; Foster-Duke KD; Hickson JA; Vaidyanathan S; Reed AD; Tovcimak AE; Guo Q; Comley RA; Lee L; Finnema SJ; Mudd SR
Mol Imaging Biol; 2022 Oct; 24(5):830-841. PubMed ID: 35482146
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis, and biological evaluation of pyrrolopyrimidine derivatives as novel Bruton's tyrosine kinase (BTK) inhibitors.
Yang M; Jiang H; Yang Z; Liu X; Sun H; Hao M; Hu J; Chen X; Jin J; Wang X
Eur J Med Chem; 2022 Nov; 241():114611. PubMed ID: 35939993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
